Annual report
7129.TEDINET S100OG2Y
Period2021-10-01 → 2022-03-31
Filed2022-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 38
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.5bn | 2021-10-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥186m | 2021-10-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥190m | 2021-10-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥534m | 2021-10-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥292m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥292m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥14.2bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥11.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.0bn | at 2021-09-30 | Cons. | Net assets |
| Cash and deposits | ¥1.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥691m | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥919m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.5bn | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥2.0bn | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥117.49 | 2021-10-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥116.61 | 2021-10-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,287.13 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 22.5% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.4% | 2021-10-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,752 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥116m | 2021-10-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥62m | 2021-10-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥3.1bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥71m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.1bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥3m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥24.86 | 2021-10-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥24.68 | 2021-10-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥17 | 2021-10-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,232.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 97.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.0% | 2021-10-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,488,300 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-10-01 → 2022-03-31 | ¥237,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-10-01 → 2022-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 22 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-10-01 → 2022-03-31 | ¥932m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-10-01 → 2022-03-31 | ¥905m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥27m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥165m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-10-01 → 2022-03-31 | ¥39m |
| Reconciling Itemsreconciling | capex | 2021-10-01 → 2022-03-31 | ¥218m |
| Reconciling Itemsreconciling | depreciation | 2021-10-01 → 2022-03-31 | ¥42m |
| Reconciling Itemsreconciling | revenue | 2021-10-01 → 2022-03-31 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-10-01 → 2022-03-31 | −¥27m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-03-31 | −¥798m |
| Medicine Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥175m |
| Medicine Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥68m |
| Medicine Businessreportable segment | employees | at 2022-03-31 | 194 pure |
| Medicine Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥8.8bn |
| Medicine Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥8.8bn |
| Medicine Businessreportable segment | segment assets | at 2022-03-31 | ¥2.9bn |
| Medicine Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥559m |
| Nursing Care Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥69m |
| Nursing Care Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥55m |
| Nursing Care Businessreportable segment | employees | at 2022-03-31 | 290 pure |
| Nursing Care Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | segment assets | at 2022-03-31 | ¥1.2bn |
| Nursing Care Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥25m |
| Nurturing Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥2.6bn |
| Nurturing Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥307m |
| Nurturing Businessreportable segment | employees | at 2022-03-31 | 1192 pure |
| Nurturing Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥6.4bn |
| Nurturing Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥6.4bn |
| Nurturing Businessreportable segment | segment assets | at 2022-03-31 | ¥7.8bn |
| Nurturing Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥362m |
| —segment total | capex | 2021-10-01 → 2022-03-31 | ¥2.9bn |
| —segment total | depreciation | 2021-10-01 → 2022-03-31 | ¥430m |
| —segment total | revenue | 2021-10-01 → 2022-03-31 | ¥18.6bn |
| —segment total | revenue external | 2021-10-01 → 2022-03-31 | ¥18.6bn |
| —segment total | segment assets | at 2022-03-31 | ¥12.0bn |
| —segment total | segment profit | 2021-10-01 → 2022-03-31 | ¥946m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-10-01 → 2022-03-31 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-10-01 → 2022-03-31 | ¥434m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-10-01 → 2022-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-10-01 → 2022-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥27m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥12.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-10-01 → 2022-03-31 | ¥985m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 794
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in operating activities | CurrentYearDuration | 918914000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf | CurrentYearDuration | -922126000 | JPY |
| Payments into time deposits inv cf | CurrentYearDuration | -35160000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYearDuration | 36000000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYearDuration | -152568000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYearDuration | 46321000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYearDuration | -1424118000 | JPY |
| Payments of construction assistance fund receivables inv cf | CurrentYearDuration | -120000000 | JPY |
| Collection of construction assistance fund receivables inv cf | CurrentYearDuration | 16499000 | JPY |
| Payments for asset retirement obligations inv cf | CurrentYearDuration | -17280000 | JPY |
| Other net inv cf | CurrentYearDuration | 38005000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -2534428000 | JPY |
| Increase decrease in short term loans payable fin cf | CurrentYearDuration | 457000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration | 2500000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -772623000 | JPY |
| Redemption of bonds fin cf | CurrentYearDuration | -41000000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYearDuration | 4695000 | JPY |
| Repayments of installment payables fin cf | CurrentYearDuration | -29224000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYearDuration | -38085000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -69351000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -63000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | 2011347000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 395833000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 691015000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 1086848000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 3 | |
| Accumulated depreciation ppe by group | CurrentYearInstant | -4998579000 | JPY |
| Directors compensations sga | CurrentYearDuration | 165221000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 542752000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 19275000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 48911000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E36714-000MedicineBusinessReportableSegmentMember | 8784052000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E36714-000NursingCareBusinessReportableSegmentMember | 3408845000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E36714-000NurturingBusinessReportableSegmentMember | 6412420000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReportableSegmentsMember | 18605318000 | JPY |
| Revenues from external customers | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 904943000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 19510261000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 19510261000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E36714-000MedicineBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E36714-000NursingCareBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E36714-000NurturingBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 26734000 | JPY |
| Transactions with other segments | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 26734000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -26734000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E36714-000MedicineBusinessReportableSegmentMember | 8784052000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E36714-000NursingCareBusinessReportableSegmentMember | 3408845000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E36714-000NurturingBusinessReportableSegmentMember | 6412420000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |